Travere Therapeutics, Inc. TVTX Business Segments — Other research and development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s business segments — other research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s business segments — other research and development?
- Travere Therapeutics, Inc. (TVTX) reported business segments — other research and development of $4.84M in Q1 2026.
- How has Travere Therapeutics, Inc.'s business segments — other research and development changed year-over-year?
- Travere Therapeutics, Inc.'s business segments — other research and development increased by 9.2% year-over-year, from $4.43M to $4.84M.
- What is the long-term trend for Travere Therapeutics, Inc.'s business segments — other research and development?
- Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s business segments — other research and development has grown at a -4.9% compound annual growth rate (CAGR), from $21.97M to $18.88M.
- What does business segments — other research and development mean?
- This metric includes miscellaneous research and development costs not categorized as direct external trial expenses or internal personnel costs, such as laboratory supplies or overhead. It provides visibility into the ancillary operational costs required to maintain a functional R&D environment.